Morgan Stanley analyst Michael Ulz initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight rating and announces Price Target of $40.
Morgan Stanley Initiates Coverage On Kyverna Therapeutics With Overweight Rating, Announces Price Target of $40
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.